Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | GABRP | O00591 | 1/20 | 0.43 |
| ▸ | GABRD | O14764 | 1/20 | 0.43 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.43 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.43 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.43 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.43 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.43 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.43 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.43 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.43 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.43 |
| ▸ | GABRE | P78334 | 1/20 | 0.43 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.43 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.43 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.43 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5221270 | 0.87 | ALDH1A1 (0.44) | ALDH1A1CYP1A2GABRPGABRDGABRA1 | |
| SCHEMBL27821918 | 0.84 | GABRP (0.50) | ALDH1A1CYP1A2GABRPGABRDGABRA1 | |
| SCHEMBL3798188 | 0.83 | ALDH1A1 (0.44) | ALDH1A1CYP1A2GABRPGABRDGABRA1 | |
| SCHEMBL3618179 | 0.82 | ALDH1A1 (0.42) | ALDH1A1CYP1A2HPGDHSD17B10MAPT | |
| SCHEMBL11338473 | 0.82 | GABRP (0.45) | ALDH1A1CYP1A2GABRPGABRDGABRA1 | |
| SCHEMBL1540028 | 0.80 | ALDH1A1 (0.49) | ALDH1A1CYP1A2HPGDHSD17B10MAPT | |
| SCHEMBL5225289 | 0.80 | ALDH1A1 (0.42) | ALDH1A1CYP1A2HPGDHSD17B10MAPT | |
| SCHEMBL859765 | 0.79 | ALDH1A1 (0.69) | ALDH1A1CYP1A2HPGDHSD17B10MAPT | |
| SCHEMBL9368491 | 0.78 | L3MBTL1 (0.42) | ALDH1A1GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL9642917 | 0.78 | RAB9A (0.40) | ALDH1A1GABRPGABRDGABRA1GABRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1610780-B2 | CYCLIC PROTEIN TYROSINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB HOLDINGS IRELAND (CH) | 2022-11-23 | — | — | EP | disclosed |
| US-20190210986-A1 | CYCLIC PROTEIN TYROSINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-07-11 | — | — | US | disclosed |
| CN-105143222-B | Glycosidase inhibitor | 默克专利有限公司 | 2018-02-02 | — | — | CN | disclosed |
| US-20180016247-A1 | CYCLIC PROTEIN TYROSINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-01-18 | — | — | US | disclosed |
| EP-3222619-A1 | CYCLIC PROTEIN TYROSINE KINASE INHIBITORS | Bristol-Myers Squibb Holdings Ireland (CH) | 2017-09-27 | — | — | EP | disclosed |
| CN-107108601-A | Glycosidase inhibitor | 阿森纽荣股份公司 | 2017-08-29 | — | — | CN | disclosed |
| US-20160264537-A1 | CYCLIC PROTEIN TYROSINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-09-15 | — | — | US | disclosed |
| US-9382219-B2 | Cyclic protein tyrosine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-07-05 | — | — | US | disclosed |
| EP-2532662-B1 | SYNTHESIS PROCESS OF DASATINIB AND INTERMEDIATE THEREOF | NANJING CAVENDISH BIO ENGINEERING TECHNOLOGY CO LTD (CN) | 2016-01-27 | — | — | EP | disclosed |
| US-9108954-B2 | Synthesis process of dasatinib and intermediate thereof | NAN JING CAVENDISH BIO-ENGINEERING TECHNOLOGY CO., LTD. (CN) | 2015-08-18 | — | — | US | disclosed |
| US-6596746-B1 | protein tyrosine kinase-associated disorders such as immunologic and oncologic disorders; dasatinib | BRISTOL-MYERS SQUIBB COMPANY | 2003-07-22 | — | — | US | disclosed |
| EP-1169038-A1 | CYCLIC PROTEIN TYROSINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-01-09 | — | — | EP | disclosed |
| WO-2000062778-A1 | CYCLIC PROTEIN TYROSINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB CO. (US) | 2000-10-26 | — | — | WO | disclosed |
| EP-0436199-B1 | Cyclopropyl derivative lipoxygenase inhibitors | ABBOTT LAB (US) | 1994-08-03 | — | — | EP | disclosed |
| US-5120752-A | N-(1-(20(3-pyridyloxy)phenyl)cyclopropyl) alkyl-N-hydroxyurea compounds, antiinflammatory agents | ABBOTT LABORATORIES (US) | 1992-06-09 | — | — | US | disclosed |
| EP-0436199-A1 | Cyclopropyl derivative lipoxygenase inhibitors | ABBOTT LABORATORIES (US) | 1991-07-10 | — | — | EP | disclosed |
| US-4602937-A | PLANT SAFENING AGENTS, ACETAMIDE HERBICIDE | MONSANTO COMPANY (US) | 1986-07-29 | — | — | US | disclosed |
| US-4602454-A | PLANT SAFENING AGENTS, SEEDS CHLOROACETAMIDE HERBICIDES | MONSANTO COMPANY (US) | 1986-07-29 | — | — | US | disclosed |
| US-4586948-A | 2,4-disubstituted-5-thiazole-carboxylic acids and derivatives | MONSANTO COMPANY (US) | 1986-05-06 | — | — | US | disclosed |
| US-4199506-A | REDUCES HERBICIDAL INJURY TO PLATNS DUE TO ACETAMIDE HERBICIDES | MONSANTO COMPANY (US) | 1980-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180016247-A1 | CYCLIC PROTEIN TYROSINE KINASE INHIBITORS | LCK, ABL1, BTK | ALDH1A1 4758/4885CYP1A2 4813/4885GABRP 1896/4885 |
| US-20190210986-A1 | CYCLIC PROTEIN TYROSINE KINASE INHIBITORS | LCK, ABL1, BTK | ALDH1A1 4758/4885CYP1A2 4813/4885GABRP 1896/4885 |
| US-20160264537-A1 | CYCLIC PROTEIN TYROSINE KINASE INHIBITORS | LCK, ABL1, BTK | ALDH1A1 4758/4885CYP1A2 4813/4885GABRP 1896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.